A blood-based study to predict the efficacy of carboplatin plus pemetrexed treatment on nonsquamous non-small cell lung cancer

UMIN ID: UMIN000008476

Registered date:25/07/2012

Basic Information

• Recruitment status: Complete: follow-up continuing
• Health condition(s) or Problem(s) studied: nonsquamous non-small cell lung cancer
• Date of first enrollment: 2012/08/01
• Target sample size: 350
• Countries of recruitment: Japan
• Study type: Observational

Outcome(s)

Primary Outcome

proteomics
microRNA analysis

Key inclusion & exclusion criteria

• Age minimum: 20years-old
• Age maximum: Not applicable
• Gender: Male and Female

Include criteria

Patients intended to be treated with carboplatin and pemetrexed are eligible for this study if they meet the following criteria;
1) Patients with pathologically proven nonsquamous non-small cell lung cancer
2) Patients with stage IIIA, IIIB or IV who are not candidates for curative radiotherapy or surgery.
3) previously untreated patients
4) Patient who has at least one or more measurable lesion by RECIST.
5) Patients aged 20 years or older.
6) Adequate organ function.
7) Patients who are considered to survive for more than 3 months.
8) Written informed consent.

Exclude criteria

1) Previous radiotherapy to primary lung cancer.
2) With active double cancer.
3) Patients whose participation in the trial is judged to be inappropriate due to phychological disorders.

Related Information

• Primary Sponsor: Central Japan Lung Study Group (CJLSG)
• Source(s) of Monetary Support: Ministry of Education, Culture, Sports, Science and Technology